Finerenone’s clinical footprint expanded after the Phase III FIND-CKD trial reported benefits in non-diabetic chronic kidney disease. Investigators found that the non-steroidal mineralocorticoid receptor antagonist slowed kidney function decline and reduced cardiovascular risk, according to the topline results described by study sponsors. The trial is positioned as one of the largest in its category, and it specifically addresses a patient population with glomerular disease where traditional pathways had fewer targeted options. By separating the signal from diabetic CKD evidence, FIND-CKD could influence how nephrologists place finerenone in earlier treatment algorithms. Clinically, the reporting focuses on deceleration of eGFR-related decline and composite cardiovascular outcomes, setting up follow-on discussions around prescribing thresholds and how quickly payors may update coverage criteria. Together with other mineralocorticoid receptor antagonist data, FIND-CKD supports a broader mechanistic rationale for blocking aldosterone signaling-driven inflammation and fibrosis beyond diabetes-linked disease.